Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-26-052863·BALYASNY ASSET MANAGEMENT L.P.
Schedule 13G ownership disclosure
Contineum Therapeutics Inc
Class A Common Stock, par value $0.001 per share · CUSIP: 21217B100
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Balyasny Asset Management L.P.
Shares: 2,312,800 · Class: 7.60%
- BAM GP LLC
Shares: 2,312,800 · Class: 7.60%
- Balyasny Asset Management Holdings LP
Shares: 2,312,800 · Class: 7.60%
- Dames GP LLC
Shares: 2,312,800 · Class: 7.60%
- Dmitry Balyasny
Shares: 2,312,800 · Class: 7.60%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-052863
- Form type
- SCHEDULE 13G
- Filer
- BALYASNY ASSET MANAGEMENT L.P.
- CIK
- CIK 1218710
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership